Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- A1926 CA 0742 CitationTarget: CathepsinsSummary: Cathepsin B inhibitor
- A1930 Apoptosis InhibitorSummary: Associate with caspase-3 inhibition
- A8162 E-64-cTarget: cysteine proteaseSummary: Inhibitor of cysteine proteinases
- A8165 Q-VD(OMe)-OPh6 CitationTarget: CaspasesSummary: Pan-caspase inhibitor
- A3126 5-R-RivaroxabanTarget: Factor XaSummary: Factor Xa (FXa) inhibitor
- A3156 Alogliptin BenzoateSummary: DPP-4 inhibitor,selective and potent,antidiabetic drug
- A3182 AnguizoleSummary: Inhibitor of HCV replication
- A3195 Asunaprevir (BMS-650032)2 CitationSummary: NS3 protease inhibitor
- A3217 BalapiravirSummary: Polymerase inhibitor,anti-HCV
- A3244 Bivalirudin TrifluoroacetateTarget: thrombinSummary: Reversible thrombin inhibitor